Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Tam, CS; Gregory, GP; Ku, M; Fleming, S; Handunnetti, SM; Lee, D; Walker, P; Perkins, A; Lew, TE; Sirdesai, S; Chua, CC; Gilbertson, M; Lasica, M; Anderson, MA; Renwick, W; Grigg, A; Patil, S; Opat, S; Friebe, A; Cooke, R; de Boer, J; Spencer, A; Ritchie, D; Agarwal, R; Blombery, P

Author(s): Tam, CS; Gregory, GP; Ku, M; Fleming, S; Handunnetti, SM; Lee, D; Walker, P; Perkins, A; Lew, TE; Sirdesai, S; Chua, CC; Gilbertson, M; Lasica, M; Anderson, MA; Renwick, W; Grigg, A; Patil, S; Opat, S; Friebe, A; Cooke, R; de Boer, J; Spencer, A; Ritchie, D; Agarwal, R; Blombery, P;
Details: Publication Year 2022-07,Volume 52,Issue #7,Page 1286-1287
Journal Title: Internal Medicine Journal
Publication Type: Correspondence
Publisher: Wiley
Keywords: Adult; Humans; *Lymphoma, Mantle-Cell/diagnosis/genetics; Mutation; Prognosis; Tumor Suppressor Protein p53/genetics
Department(s): Haematology; Pathology
PubMed ID: 35879233
Publisher's Version: https://doi.org/10.1111/imj.15851
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-04-11 08:06:35

Last Modified: 2025-04-11 08:08:00